FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/03/023783 [Registered on: 05/03/2020] Trial Registered Prospectively
Last Modified On: 21/09/2021
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Non-randomized, Active Controlled Trial 
Public Title of Study   A study of a safe and non-invasive method for preventive screening for breast cancer and monitoring of breast cancer patients. 
Scientific Title of Study   A prospective study to evaluate the effectiveness of Thermalytixâ„¢ (AI-based thermographic screening solution) for preventive screening, diagnosis, and monitoring of breast cancer patients. 
Trial Acronym  SANT20 
Secondary IDs if Any  
Secondary ID  Identifier 
NIR-RCC-THERMAL Version 1.0 Dated Jan 10th 2019   Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Venugopal M 
Designation  Professor and Head of Department 
Affiliation  Regional Cancer Center (RCC), Thiruvananthapuram 
Address  Department of Radiodiagnosis, Regional Cancer Centre, Medical College Campus, Post Bag No.2417, Thiruvananthapuram

Thiruvananthapuram
KERALA
695011
India 
Phone  9349981765  
Fax    
Email  drvenurcc@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Venugopal M 
Designation  Professor and Head of Department 
Affiliation  Regional Cancer Center (RCC), Thiruvananthapuram 
Address  Department of Radiodiagnosis, Regional Cancer Centre, Medical College Campus, Post Bag No.2417, Thiruvananthapuram

Thiruvananthapuram
KERALA
695011
India 
Phone  9349981765  
Fax    
Email  drvenurcc@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Geetha Manjunath  
Designation  Chief Executive Officer  
Affiliation  NIRAMAI Health Analytix Pvt Ltd 
Address  A7-506, Elita Promenade, J P Nagar 7th Phase, Bangalore

Bangalore
KARNATAKA
560078
India 
Phone  9880118379  
Fax    
Email  geetha@niramai.com  
 
Source of Monetary or Material Support  
NIRAMAI Health Analytix Pvt Ltd, A7-506, Elita Promenade, JP Nagar 7th Phase, Bangalore - 560078 
 
Primary Sponsor  
Name  NIRAMAI Health Analytix Pvt Ltd 
Address  A7 506, Elita Promenade, J P Nagar, 7th Phase Bengaluru – 560078 Karnataka, India 
Type of Sponsor  Other [Health Technology Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Venugopal M  Regional Cancer Centre (RCC), Trivandrum  Department of Radiodiagnosis, Level 2, A2 23, Medical College Campus, Post Bag No 2417, Thiruvananthapuram, India – 695011
Thiruvananthapuram
KERALA 
9349981765

drvenurcc@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Human Ethics Committee, RCC  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Nil  Nil 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Female 
Details  1. Women presenting with or without symptoms of breast cancer
2. Women with previous history of breast cancer or currently undergoing treatment for breast cancer who present for follow-up
3. Women who are willing to give written informed consent for study participation
4. Women who are ready to comply with the study related visits and procedures 
 
ExclusionCriteria 
Details  1. Subjects who are pregnant
2. Subjects who are lactating
3. Subjects who have undergone Chemotherapy in the last 2 weeks at the time of study enrollment
4. Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Thermalytix in asymptomatic and symptomatic women who have not been diagnosed earlier for breast cancer   Every 6 months for 3 years 
 
Secondary Outcome  
Outcome  TimePoints 
Performance of Thermalytix in women previously diagnosed with breast cancer.  Every 6 months for 3 years 
Influence of patient characteristics on diagnostic accuracy of Thermalytix©.
Patient characteristics will include:
(a) Age
(b) Lesion type
(c) Pathologic diagnosis
(d) Menopausal and hormonal status
(e) Breast density
(f) Family history
(g) Other risk factors 
3 years 
Recommend how Thermalytix can be used to complement standard breast cancer screening procedure  3 years 
 
Target Sample Size   Total Sample Size="3000"
Sample Size from India="3000" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   09/03/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details
Modification(s)  
Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

Cancer of the breast is the most common cause of cancer-related death in India. Detecting breast cancer at early stages is crucial for providing treatment and reducing disease morbidity and mortality. Mammography is the only known method to reduce breast cancer mortality. However, mammography has certain limitations. It is not recommended to be used on women under the age of 45 years, cannot be used on lactating/pregnant women, is less effective on women with high density of breast, and repeated mammography comes with a risk of radiation-induced breast cancer.  Mammography in correlation with sono-mammography is widely used currently for screening in hospitals.

Infrared imaging of the breast or thermography is an imaging technique which detects suspected malignancy based on thermal changes on the chest. Due to increased blood circulation and metabolic activity of the tumour, the temperature of the tumour tissue is higher than the surrounding areas. This thermal information is captured by a high-resolution thermal camera. A thermal image provides a visual representation of the temperature distribution and can be used for clinical interpretation of abnormal breast conditions as an adjunct modality. Certain trained clinicians who are certified thermologists can interpret these breast thermograms to determine its malignancy or benign condition. However, manual interpretation of these thermograms is very cumbersome and error prone. Thermalytixâ„¢, a novel artificial intelligence and machine learning-based CAD system, is a new method of interpreting thermal images that has shown higher sensitivity and comparable specificity when compared with mammography in early experiments. Thermalytixâ„¢ is a non-contact, non-invasive, radiation-free, affordable and is also applicable to women under 45 years and those with dense breasts.

In this study, the entry criteria for the study will be asymptomatic women, symptomatic women who show possible symptoms of suspected breast cancer, such as pain, lump and so on, and women who come for follow-up after diagnosis/treatment of breast cancer. The primary objectives of the study are to assess a non-inferiority of sensitivity of Thermalytixâ„¢ over the sensitivity of standard screening procedures by not more than 10% and study comparative diagnostic performance of Thermalytixâ„¢ with standard screening modalities in asymptomatic and symptomatic women. The endpoint measurements would be sensitivity, specificity, PPV, and NPV in the detection of breast cancer in women without an earlier history of breast cancer. The secondary objectives include evaluating the performance of Thermalytixâ„¢ in women previously diagnosed with breast cancer, study the influence of effects of patient characteristics on diagnostic accuracy and the evaluation of changes in Thermalytix scores of women who come for follow-up after diagnosis or treatment of breast cancer across various visits. Also, Thermalytixâ„¢ as a complement to the standard modalities in breast cancer will be evaluated. A publication at the end of each year will be targeted.

This protocol for human research study will be conducted according to standards of effective Good Clinical Practice (International Conference on Harmonization [ICH] Guidelines), applicable Indian regulations and applicable Ethical Guidelines for Biomedical Research involving Human Participants issued by the Indian Council of Medical Research. The trial protocol and study participant documentation were reviewed and approved by the Institutional Ethical Review Boards of the participating trial site.

 
Close